

Notice of Allowability

Application No.

09/743,825

Applicant(s)

CHAQUI ET AL.

Examiner

MINH-TAM DAVIS

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to interview of 05/08/06.
2. ☒ The allowed claim(s) is/are 2-3, 5, 10, 12, 17, 19, 27-31, 33, renumbered as 1-13.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☒ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413), Paper No./Mail Date 05/08/06.
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other PTO-90

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with NANCY AXELROD on 05/08/06 and 05/16/06.

The application has been amended as follows:

In the specification:

1) The following continuation data was inserted to the first line after the title, on page 1 of the specification:

RELATED APPLICATIONS

This application is a 371 national stage Application of PCT/US99/16831, filed on 07/23/1999, which claims benefit of Application Serial Number 60/094,137, filed on 07/24/1998, now abandoned.

2) The specification was amended as follows:

In the specification, page 5, line 28th, after the first "transcript" word ---- (SEQ ID NO:1 and SEQ ID NO:2, respectively) --- was inserted.

In the specification, page 5, line 28th, after "the 5 kb transcript" --- (SEQ ID NO:3 and SEQ ID NO:4, respectively) --- was inserted.

In the claims:

Claims 1, 4, 6-9, 11, 13-16, 18, 20-26, 32, 34-40 were cancelled.

Claim 19 was amended as follows: "from a primary prostate tumor" was deleted, and --- of a tissue from a primary prostate cancer --- was inserted.

Claim 30 was amended as follows: "from a primary prostate tumor" was deleted, and --- of a tissue from a primary prostate cancer --- was inserted.

2. The amendment of claims 19, 30 is supported on page 3, last paragraph, and page 13, example 1. The amendment obviates the 112, first paragraph, new matter issue for the language "a sample from a primary prostate tumor".

3. The request of 11/09/04 and 05/26/06 to correct inventorship, by adding Michael R. Emmert-Buck as an inventor is granted and entered (see the enclosed PTO-90).

4. The following is an Examiner's statement of reasons for allowance:

The claimed nucleic acid and method of detecting prostate cancer is novel. The closest prior art for SEQ ID NO:1 is the cDNA SEQ ID NO:21(HP10302) of 2373 nucleotides in length from a liver cDNA library, as taught by Kato et al (WO 98/21328-A2, p. 56-57, of record), which is only 99.5% similar to SEQ ID NO:1 of 2326 nucleotides in length of the instant application, from nucleotide 64 to nucleotide 2317 of SEQ ID NO:1 of the instant application (see the Office action of 05/05/04, on pages 19-20). Moreover, Kato et al do not teach or suggest that SEQ ID NO:21 is overexpressed in prostate cancer, nor a method for detecting prostate cancer, using SEQ ID NO:21. The closest prior for SEQ ID NO:7 is a 20 nucleotide primer, taught by Kachiku (JP08154685-A, published on 06/18/1996), which is only 58% similar to SEQ ID NO:7 (see MPSRCH search report, 2006, us-09-743825-7.rng, pages 7-8). The closest prior for SEQ ID NO: 8 is a 20 nucleotide primer, taught by Buell et al (US 6,509,163-B1), which is only 61% similar to SEQ ID NO:8 (see MPSRCH search report, 2006, us-09-743825-8.rng, page

Art Unit: 1642

4). The closest prior for SEQ ID NO:10 is a 20 nucleotide primer, taught by Feder et al (US 6,849,399-B1), which is only 63% similar to SEQ ID NO:10 (see MPSRCH search report, 2006, us-09-743825-10.rng, page 4).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, JEFFREY SIEW can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MINH TAM DAVIS
May 31, 2006


JEFFREY SIEW
SUPERVISORY PATENT EXAMINER

Application/Control Number: 09/743,825
Art Unit: 1642

Page 5

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT	PAPER
----------	-------

20060512

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The request of 11/09/04 and 05/26/06 to correct inventorship, by adding Michael R. Emmert-Buck as an inventor, in addition to the existing inventors Rodrigo F. Chaqui, Kristina A. Cole, and Lance A. Liotta is granted and entered.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, JEFFREY SIEW can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MINH TAM DAVIS

May 31, 2006

VENABLE LLP575 7th Street, NW
Washington, DC 20004-1601Telephone 202-344-4000
Facsimile 202-344-8300

www.venable.com

TO:
Examiner Minh-Tam Davis
U.S. PTOFAX NUMBER:
(571) 273-0830

PHONE NUMBER:

SENDER:
Nancy J. AxelrodSENDER'S FAX NUMBER:
202-344-8300SENDER'S PHONE NUMBER:
202-344-8334SENDER'S ASSISTANT:
Lili FroehlingASSISTANT'S PHONE NUMBER:
202-344-4284DATE:
5/16/2006CLIENT/MATTER NUMBER:
31978-202420PAGES, EXCLUDING COVER:
9

MESSAGE:

Re: S/N 09/743,825

Dear Tam,

In accordance with your telephonic request today, enclosed is another copy of the paper we filed in the above-referenced application on June 9, 2005. This paper provides copies of references that had been cited by the Examiner, and that had apparently been lost by the PTO.

With best regards,

Nancy Axelrod, Ph.D.
Patent Agent
VENABLE LLP
575 7th Street, N.W.
Washington, DC 20004-1601
202-344-8334 direct
202-344-4000 main
202-344-8300 fax
<http://www.venable.com>
<mailto:njaxelrod@venable.com>

If you require assistance with this transmission, please contact the sender.

This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. postal service.

U.S. Treasury Circular 230 Notice: Any tax advice contained in this facsimile transmission (including the cover sheet), unless otherwise stated, was not intended or written to be used, and cannot be used, for the purpose of (a) avoiding tax-related penalties; or (b) promoting, marketing or recommending to another party any tax-related matter addressed herein. We provide this disclosure on all faxes to ensure compliance with new standards of professional practice, pursuant to which certain tax advice must meet requirements as to form and substance. Thank you.

127005

Venable Filing Number

Attorney/LAA: NJA/rahs
 PTO Due Date: _____
 Date Filed: June 9, 2005

TM Official
 Gazette Date: _____

Atty. Docket No: 31978-202420
 Re: "PB39, A GENE DYSREGULATED IN PROSTATE CANCER, AND USES THEREOF"
R. CHUAQUI et al.
 Application No: 09/743,825
 Patent No.: _____
 Appl'n Filing Date: JANUARY 15, 2002
 Issue Date: _____

The following items were received from Venable, Washington, D.C., by the U.S. Patent & Trademark Office:

U.S. PTO FEES ENCLOSED

- ☐ Transmittal Form (PTO/SB/21)
☐ Fee Transmittal Letter
☐ New U.S. Utility Application (_____ pages of specification/claims)
☐ Submission Of Formal Drawing (Sheets - Figs.)
☐ Invention Declaration
☐ U.S. National Stage Application of PCT Application
☐ Translation of International Application
☐ New U.S. TM Application (_____ specimens)
☐ Rule 53(d) Continued Prosecution Application
☐ Substitute Specification
☐ Rule 53(b) Continuation or Divisional Application (*attach copy of specification, claims, drawings & declaration*)
☐ Priority Document-Cert. Copy of Appln.#: _____ ; Country _____
☐ Date Filed: _____
☐ Request for Continued Examination (RCE) under 37 CFR 1.114
☐ Request for Reconsideration
☐ Application Data Sheet
☐ Assignment w/Cover Sheet
☐ IDS w/ PTO/SB/08A
☐ Status Inquiry
☒ **RESPONSE TO NOTICE UNDER 37 C.F.R. 1.251**
☒ **COPY NOTICE UNDER 37 C.F.R. 1.251 w/ REFERENCE**
☐ Notice of Appeal
☐ Appeal Brief (*in triplicate*)
☐ ☐ Reply Brief (*in triplicate*) / ☐ Request for Oral Hearing
☐ Confirmation of Hearing Petition
☐ Issue Fee Transmittal
☐ Certificate of Correction
☐ Maintenance Fee Transmittal
☐ Power of Attorney
☐ Response to Notice to File Missing Parts
☐ Response to Notice to File Missing Requirements
☐ Response to Restriction Requirement
☐ Petition to Revive
☐ Sequence Listing - CDR Enclosed? ☐ Yes ☐ No
☐ Request for Non-Publication
☐ Request to Rescind Non-Publication Request
☐ Terminal Disclaimer
☐ Notice of Opposition (*Please list all documents in Other section*)
☐ Amendment to Alleged Use

_____ Filing Fee
 _____ Surcharge Fee
 _____ Additional Claim Fee
 _____ Multiple Dependent Claim Fee
 _____ IDS Fee
 _____ Extension Fee
 _____ Notice of Appeal Fee
 _____ Brief on Appeal Fee
 _____ Oral Hearing Request Fee
 _____ Petition Fee
 _____ Issue Fee
 _____ Publication Fee
 _____ Maintenance Fee
 _____ TM Statement of Use
 _____ 8 Affidavit Fee
 _____ 8 and 15 Affidavit
 _____ TM Renewal Application Fee
 _____ TM Extension of Time Fee

-NONE- Total Fees Paid

☐ Check Number _____ Attached
☐ Charge Any Fees Due to Deposit Account
 22-0261*
☐ Yes ☐ No

*If the Deposit Account was used, was a copy of this form sent to Accounting?

::ODMA\PCDOCS\DC2DOCS\1655795\1

PATENT

Attorney Docket No.: 31978-202420

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re application of: R. Chuaqui *et al.*

: Examiner: Minh-Tam DAVIS

Serial No.: 09/743,825

: Group Art Unit: 1642

Filed: January 15, 2002

: USPTO Customer No.: **45323**For: PB39, A GENE DYSREGULATED IN
PROSTATE CANCER, AND USES
THEREOF


: Confirmation No. 8611

RESPONSE TO NOTICE UNDER 37 C.F.R. 1.251Assistant Commissioner of Patents
P.O. Box 1450
Alexandria, VA. 22313-1450**ATTENTION: MAIL STOP AF**

Sir:

In response to the Notice Under 37 C.F.R. 1.251, applicant have provided copies of the last two references from the "List of References Cited by Examiner (PTO-892), dated May 5, 2004. The copy of each paper is a complete and accurate copy of applicant's record of such paper.

Respectfully submitted,

Date: June 9, 2005
Nancy J. Axelrod, Ph.D.
Registration No. 44,014
VENABLE LLP
575 7th Street, NW
Washington, D.C. 20004-1601
Direct telephone: (202) 344-8334
Telefax: (202) 344-8300

::ODMA\PCDOCS\DC2DOCS\1654471\1

**UNITED STATES PATENT AND TRADEMARK OFFICE**

COMMISSIONER FOR PATENTS

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

NOTICE UNDER 37 CFR 1.251 - Pending Application

☐ The file on the cover sheet cannot be located after a reasonable search. Therefore, the Office is initiating the reconstruction of the file of the above-identified application pursuant to the provisions of 37 CFR 1.251.

Applicant is hereby requested to provide a copy of applicant's record (if any) of all of the correspondence between the Office and applicant for the above-identified application (except for U.S. patent documents), a list of such correspondence, and a statement that the copy is a complete and accurate copy of applicant's record of all of the correspondence between the Office and the applicant for the above-identified application (except for U.S. patent documents), and whether applicant is aware of any correspondence between the Office and applicant for the above-identified application that is not among applicant's records.

☒ The following paper(s) pertaining to the above-identified application cannot be located after a reasonable search:

The last two references from the "List of References Cited by Examiner (PTO-892)," dated 5/5/04:

- MPSRCH sequence search report, 2004, us-09-743-825-1.mg, pages 4-6
- Genbank Sequence Database, Accession No: G22380, and MPSRCH search report, 2004, us-09-743-825-7.rge, p. 1-2, and us-09-743-825-10.rge, p. 1-2

Therefore, the Office is initiating the reconstruction of such paper(s) pursuant to the provisions of 37 CFR 1.251.

Applicant is hereby requested to provide a copy of the paper(s) listed above and a statement that the copy of such paper(s) is a complete and accurate copy of applicant's record of such paper(s).

If applicant does not possess any record of the correspondence between the Office and the applicant for the file listed on the cover sheet or any copy of the paper(s) listed, applicant must reply to this notice by providing a statement that applicant does not possess any record of the correspondence between the Office and the applicant for the above-identified application.

☐ A printout from PALM of the contents of the file of the above-identified application is included with this notice.

Direct the reply to this notice to:

U. S. Patent and Trademark Office
Mail Stop: Duplicates
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Direct questions concerning this notice to:

Image Assistance Center/ Customer Service

1-(888)-786-0101

PTO Doc. Code: R251.NTC (Rev. 03/05)

COMMISSIONER FOR PATENTS

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

In re Application of: RODRIGO F. CHAQUI et al.
Application No.: 09/743825
Filing Date: 01/15/2002
Title: PB 39, A GENE DYSREGULATED IN PROSTATE CANCER,
AND USES THEREOF
Direct to: U. S. Patent and Trademark Office
Mail Stop: Duplicates
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

NOTICE UNDER 37 CFR 1.251 -- Pending Application

Statement (check the appropriate box):

☐ The copy submitted with this reply is a complete and accurate copy of applicant's record of all of the correspondence between the Office and the applicant for the above-identified application (except for U.S. patent documents), and applicant is not aware of any correspondence between the Office and applicant for the above-identified application that is not among applicant's records.

☐ The copy of the paper(s) listed in the notice under 37 CFR 1.251 is/are a complete and accurate copy of applicant's record of such paper(s).

☐ The papers produced by applicant are applicant's complete record of all of the correspondence between the Office and the applicant for the above-identified application (except for U.S. patent documents), and applicant is not aware of any correspondence between the Office and the applicant for the above-identified application that is not among applicant's records.

☐ Applicant does not possess any record of the correspondence between the Office and the applicant for the above identified application.

June 9, 2005
Date

Nancy Axelrod
Signature

Nancy J. Axelrod, Reg. No. 44,014
Typed or printed name

A Copy of this notice should be returned with the reply.

Burden Hour Statement: This collection of information is required by 37 CFR 1.251. The information is used by the public to reply to a request for copies of correspondence between the applicant and the USPTO in order to reconstruct an application file. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 60 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

PTO Doc Code: R251.RES (Rev. 03/05)

P.O. Box 1450, Alexandria, Virginia 22313-1450 - www.USPTO.GOV

Page 6

51 5

NCBI Sequence Viewer



Nucleotide

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	Books
Search		Nucleotide	for	Go		Clear		
Limits		Preview/Index		History		Clipboard		Details
Display	default	Show	20	Send to	File	Get Subsequence		Features

1: G22380. human STS WI-1700...[gi:1342706]

LOCUS G22380 321 bp DNA linear STS 31-MAY-1996
DEFINITION human STS WI-17004, sequence tagged site.
ACCESSION G22380
VERSION G22380.1 GI:1342706
KEYWORDS STS; STS sequence; primer; sequence tagged site.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 321)
AUTHORS Hudson, T.
TITLE Whitehead Institute/MIT Center for Genome Research; Physically
Mapped STS
JOURNAL Unpublished (1995)
COMMENT
Contact: Thomas Hudson
Whitehead Institute/MIT Center for Genome Research
Whitehead Institute for Biomedical Research
9 Cambridge Center, Cambridge MA 02142 USA
Tel: 617 252 1900
Fax: 617 252 1902
Email: thudson@genome.wi.mit.edu

Primer A: TTTATAAATCTACGGCCATGGC
Primer B: CTGGATGACAGGCAATCAAG
STS size: 101
PCR Profile:

Presoak:
Denaturation:
Annealing: 56 degrees C
Polymerization:
PCR Cycles: 35
Thermal Cycler:

Protocol:

Template: 10 ng
Primer: each 5 pM
dNTPs: each 4 nM
Taq Polymerase: 0.025 units/ul
Total Vol: 20 ul

Buffer:

MgCl2: 1.5 mM
KCl: 50 mM
Tris-HCl: 10 mM
pH: 9.3

Derived from dbEST (genbank accession R00504).

FEATURES
source Location/Qualifiers
1..321

ance Viewer

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="291.1 cR from top of Chr11 linkage group"

35..135

35..56

complement(116..135)

STSprimer bindprimer bind

IGIN

```
1 tncagtcttt acaaaaatag aacttctctt ggtatttata aatctacggc catggctcta
61 tgtgcatggt acaggtagaa aagccatatg gggcactcct tttggttgct caggccttga
121 ttgectgtca tccagggccc ttggtctgag aagtctatgc ggtcacctca gagccgctaa
181 gcacottcag tgggcccata ccattggcgg cgtactcctg ctggagccgg gcacggtaat
241 agaagaggta ggggaaggcaa caggaatccc aggggagtga ggaatagcag gaggccccag
301 atttcacctt tagggggcaa g
```

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH